Article
Brochure
Executive Resource
Insight Hub
Video
Ext. Publication
Home /
Insights & Resources
Insights & Resources
Start exploring insights from across the industries we serve, featuring the latest industry trends, compliance alerts, tax and accounting news and much more.
- Alternative Investments
- Banking
- Blockchain & Digital Assets
- Construction
- Consumer Products
- Energy Transition
- Financial Services
- Food & Beverage
- General Business
- Government
- Health Care
- Higher Education
- Hospitality & Entertainment
- Industrial Products
- Insurance
- Life Sciences
- Not-for-Profit
- Oil & Gas
- Oilfield Services
- Real Estate
- Renewable Fuels
- Technology
- Transportation & Logistics
- Accounting Advisory
- Artificial Intelligence
- Asset Management Consulting
- Asset Tracing
- Cybersecurity
- Data Privacy
- Digital Transformation
- Energy Compliance
- ESG Strategy & Consulting
- Family Law
- Forensics & Litigation
- Government Consulting
- Health Care Valuation
- IT Advisory
- Risk Advisory
- Transaction Advisory
- Trust & Estate
- Valuation
As risk evolves, life science companies must adapt valuation methods. Learn to better align risk, value and strategy in your decision-making process.
Public-sector procurement scandals show how lax vendor controls endanger taxpayer dollars. Learn key red flags and practical steps to reduce risk.
Weaver supported an aviation management firm with sell-side financial and tax assistance, saving the client over $1 million in post-close adjustments.
J.P. Morgan's Q1 2025 biopharma and medtech reports reveal larger deals, global growth and financial strategies shaping the life sciences industry.
Explore how proposed Medicaid cuts could impact health care valuations, reimbursement models and financial stability across various provider segments.
PodcastExplore key trends in government health care, from funding challenges to innovation, and how policies will shape the future of patient care.
J.P. Morgan’s Q3 2024 Biopharma Report highlights robust venture investments, shifting licensing trends and a resurgence in IPO activity.
The medical technology, or medtech, industry is poised for a transformative year despite soft IPO activity the first half of 2024. Learn more here.
The biopharma industry has experienced a resurgence the first part of 2024. J.P. Morgan’s Q2 report shares critical insights into the future of the industry.
WebinarNavigating the federal grants process can be complex. Our Center of Excellence – Not-for-Profit Consulting team dives into the ever-changing and multifaceted world of federal grants from how to determine which grants best fit your mission to ensuring compliance with federal requirements and reporting.
In a business sale, due diligence is critical to mitigate the risk of unexpected tax issues for buyers and sellers. Find out key components of tax due diligence.
During this webinar, we discuss considerations for your organization that will help you be prepared in the event you are faced with responding to a fraud allegation.
